Abstract:AIM:To explore whether olanzapine alters bone mineral density (BMD), glucose, and lipid metabolism in schizophrenia patients.METHODS:This study enrolled 150 patients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), including 101 patients who had over 6-month history of olanzapine use (olanzapine-treated group) and 49 patients who had no history of antipsychotic use (first episode drug-naïve group). 71 subjects with age- and gender-matched healthy volunteers (healthy control group) were also enrolled. All study subjects were from the Chinese Han population recruited in the Second Xiangya Hospital from January 2015 to January 2016. Demographic and physical examination data were collected from all subjects. BMD measurements of the radius+ulna, lumbar spine (L1-4), and left hip were performed via a dual-energy X-ray absorptiometry test. Serum lipid, glucose, and insulin levels were analyzed. Psychopathology profiles in all enrolled schizophrenia patients were assessed by the positive and negative syndrome scale (PANSS).RESULTS:There was no significant difference in age, gender, activity intensity, smoking, or drinking among the three groups. In the majority of evaluated bone areas, the BMD values in olanzapine-treated or drug-naïve patients were lower than those in the control group. However, BMD values in the drug-naïve group showed no difference or even decreased as compared with those in the olanzapine-treated group. Among the olanzapine-treated group, although not observed in every tested region, a positive correlation was found of BMI or HOMA-IR with BMD. Stepwise multiple linear regression analysis revealed independent predictive factors associated with BMD in groups/subgroups of schizophrenia patients or healthy controls, including gender, TG, BMI, body weight, HOMA-IR, and FBG.CONCLUSIONS:Schizophrenia, but not the long-term use of olanzapine, correlates with BMD loss in schizophrenia patients. Elevated BMI, TG, FBG, and insulin levels might protect these patients against bone degradation. Our work provides new information to improve the understanding, prevention, and treatment of osteoporosis in schizophrenia patients.

The relationship of cognitive function and metabolic syndrome in stable schizophrenia patients under long-term olanzapine treatment

Correlation of Orexin-A and Brain-Derived Neurotrophic Factor Levels in Metabolic Syndrome and Cognitive Impairment in Schizophrenia Treated with Clozapine

Effects of paliperidone extended-release tablets (paliperidoneer) and olanzapine on metabolic profile, weight, insulin resistance and beta-cell function in schizophrenic patients: a randomized 12-week study

Metabolic Adverse Effects of Olanzapine on Cognitive Dysfunction: A Possible Relationship Between BDNF and TNF-alpha

Investigation of metabolic syndrome in inpatients of chronic schizophrenia with long-term clozapine treatment

Association Between Olanzapine Concentration and Metabolic Dysfunction in Drug-Naive and Chronic Patients: Similarities and Differences

Metabolic Effects Of 7 Antipsychotics On Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial

Clinical patterns of metabolic syndrome in young, clinically stable, olanzapine-exposed patients with schizophrenia

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients with Schizophrenia.

Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users

A related study of social functioning and quality of life in patients with schizophrenia with metabolic syndrome

A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients

Association Between Metabolic Risk Factors and Cognitive Impairment in Schizophrenia Based on Sex.

Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients.

Metabolic abnormality in patients with drug-naive schizophrenia: Case-control study

Olanzapine-Induced Weight Gain and Glycolipid Metabolism Aberrations in First-Episode and Antipsychotic-Naïve Schizophrenia Patients: A Longitudinal Study

The relationship between body mass index and cognitive function among patients with first-ever occurrence of schizophrenia after treatment

The effects of risperidone and olanzapine on the glucose metabolism and lipid metabolism in elderly patients with schizophrenia

Evaluation of Clinical Correlation between Insulin Resistance and Antipsychotic Drug Therapy in Patients with Schizophrenia

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study

Influencing factors of different metabolic status in hospitalized patients with schizophrenia